Latest Insider Transactions at Palisade Bio, Inc. (PALI)
This section provides a real-time view of insider transactions for Palisade Bio, Inc. (PALI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PALISADE BIO, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PALISADE BIO, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 01
2022
|
John David Finley CEO, CFO, Director |
BUY
Open market or private purchase
|
Direct |
19,481
+11.58%
|
$0
$0.14 P/Share
|
|
Aug 23
2022
|
John David Finley CEO, CFO, Director |
BUY
Open market or private purchase
|
Direct |
7,350
+5.38%
|
$0
$0.16 P/Share
|
|
Aug 16
2022
|
Thomas Hallam Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
40,000
+40.99%
|
$0
$0.25 P/Share
|
|
Aug 16
2022
|
John David Finley CEO, CFO, Director |
BUY
Open market or private purchase
|
Direct |
100,000
+45.07%
|
$0
$0.25 P/Share
|
|
Apr 29
2022
|
John David Finley CEO, CFO, Director |
BUY
Other acquisition or disposition
|
Indirect |
12,545
+24.4%
|
-
|
|
Mar 29
2022
|
Michael John Dawson Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+50.0%
|
$15,000
$1.14 P/Share
|
|
Mar 28
2022
|
Thomas Hallam Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+36.24%
|
$10,000
$1.18 P/Share
|
|
Mar 24
2022
|
John David Finley CEO, CFO, Director |
BUY
Open market or private purchase
|
Direct |
7,500
+25.51%
|
$7,500
$1.09 P/Share
|
|
Sep 21
2021
|
Thomas Hallam Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
6,000
+44.14%
|
$12,000
$2.49 P/Share
|
|
Sep 21
2021
|
John David Finley CEO, CFO, Director |
BUY
Open market or private purchase
|
Direct |
2,000
+12.2%
|
$4,000
$2.44 P/Share
|
|
Sep 10
2021
|
Robert J. Trenschel Director |
BUY
Open market or private purchase
|
Direct |
2,142
+12.5%
|
$4,284
$2.98 P/Share
|
|
Sep 09
2021
|
Robert J. Trenschel Director |
BUY
Open market or private purchase
|
Direct |
3,400
+20.91%
|
$6,800
$2.89 P/Share
|
|
Sep 08
2021
|
Robert J. Trenschel Director |
BUY
Open market or private purchase
|
Direct |
5,000
+34.59%
|
$10,000
$2.75 P/Share
|
|
Sep 07
2021
|
Robert J. Trenschel Director |
BUY
Open market or private purchase
|
Direct |
2,707
+37.79%
|
$5,414
$2.78 P/Share
|
|
Aug 31
2021
|
Robert J. Trenschel Director |
BUY
Open market or private purchase
|
Direct |
1,750
+50.0%
|
$3,500
$2.75 P/Share
|
|
Aug 27
2021
|
John David Finley CEO, CFO, Director |
BUY
Open market or private purchase
|
Direct |
10,000
+34.49%
|
$20,000
$2.64 P/Share
|
|
Apr 27
2021
|
John David Finley CEO, CFO, Director |
BUY
Grant, award, or other acquisition
|
Indirect |
26,322
+50.0%
|
-
|
|
Apr 27
2021
|
John David Finley CEO, CFO, Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,396
+50.0%
|
-
|
|
Apr 27
2021
|
Thomas Hallam Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,592
+50.0%
|
-
|
|
Apr 27
2021
|
Robert J. Trenschel Director |
BUY
Grant, award, or other acquisition
|
Indirect |
304,479
+50.0%
|
-
|